Lee Soyoung, Rodney Ellis, Traughber Bryan, Biswas Tithi, Colussi Valdir, Podder Tarun
Department of Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH.
Department of Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH; Department of Radiation Oncology, Case Western Reserve University, University Hospitals Seidman Cancer Center, Cleveland, OH.
Brachytherapy. 2017 Nov-Dec;16(6):1192-1198. doi: 10.1016/j.brachy.2017.09.001. Epub 2017 Oct 6.
To investigate the dosimetric effects due to interfractional changes in catheter position and variation in patient's anatomy during the course of interstitial high-dose-rate (HDR) brachytherapy.
A total of 15 patients with either cervical or vaginal cancer underwent interstitial HDR brachytherapy. Interstitial catheters and fiducials were placed under fluoroscopy and intraoperative 3T MRI to confirm the desired catheter placement for adequate target volume coverage. Single plan was generated from first-fraction CT fused with the MRI and used for all fractions of treatment. CT image was acquired before each treatment and registered to the first-fraction CT. Displacement of fiducials and catheters was calculated for each fraction and its effects on dosimetric parameters such as dose covering 90% for high-risk clinical target volume and intermediate-risk clinical target volume and dose to the 2 cm of the volume for bladder, rectum, sigmoid, and bowel were studied.
Average movements of fiducials and catheters were 1.6 mm (range: 0.1-7.1 mm) and 1.7 mm (range: 0.1-4.5 mm), respectively. Overall, deviation of the delivered dose to the target in each fraction was insignificant for all patients (p-value: 0.66 for high-risk clinical target volume and 0.87 for intermediate-risk clinical target volume). The mean dose to organs at risk showed maximum difference up to 0.9, 2.7, 1.6, and 2.1 Gy for bladder, rectum, sigmoid, and bowel, respectively (p-value: 0.88, 0.34, 0.68, and 0.85 for bladder, rectum, sigmoid, and bowel, respectively).
The interfractional dosimetric variation for both target and organs at risk was within clinically acceptable limit throughout the entire course of interstitial HDR-Syed brachytherapy. Only 6% of cases performed replanning, which could be readily identified using CT imaging.
研究在间质高剂量率(HDR)近距离放射治疗过程中,分次治疗间导管位置变化及患者解剖结构变异所产生的剂量学影响。
共有15例宫颈癌或阴道癌患者接受了间质HDR近距离放射治疗。在荧光透视和术中3T磁共振成像引导下放置间质导管和基准标记,以确认所需的导管位置,从而充分覆盖靶区。通过将首次分次CT与磁共振成像融合生成单一计划,并用于所有分次治疗。在每次治疗前采集CT图像,并将其与首次分次CT进行配准。计算每个分次中基准标记和导管的位移,并研究其对剂量学参数的影响,如高危临床靶区和中危临床靶区90%体积的覆盖剂量,以及膀胱、直肠、乙状结肠和肠道2cm体积的剂量。
基准标记和导管的平均移动分别为1.6mm(范围:0.1 - 7.1mm)和1.7mm(范围:0.1 - 4.5mm)。总体而言,所有患者各分次中实际给予靶区的剂量偏差均不显著(高危临床靶区p值为0.66,中危临床靶区p值为0.87)。膀胱、直肠、乙状结肠和肠道的平均受量差异最大分别为0.9、2.7、1.6和2.1Gy(膀胱、直肠、乙状结肠和肠道的p值分别为0.88、0.34、0.68和0.85)。
在整个间质HDR - 赛义德近距离放射治疗过程中,靶区和危及器官的分次间剂量学变化均在临床可接受范围内。仅6%的病例进行了重新计划,通过CT成像可轻易识别这些病例。